ArticleTranslational cancer research2026
Macrophage-associated SLAMF9 is a potential therapeutic target for glioma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The signaling lymphocytic activation molecule family (SLAMF) members have recently been demonstrated to be potential targets in malignant tumors. The aim of this study is to explore the role of SLAMF member 9 (SLAMF9) in glioma. Methods: Datasets from The Cancer Genome Atlas (TCGA) database were downloaded, and the correlation between SLAMF9 expression and the overall survival (OS) of glioma patients was analyzed. A tissue chip including 139 tumor tissues from glioma patients for immunohistochemistry (IHC) staining was used to detect the protein expression of SLAMF9, and the relationships between SLAMF9 expression and OS, disease-free survival (DFS), and clinicopathological features were analyzed. Multiplex immunofluorescence and quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry analysis, and bioinformatics analysis were used to detect the potential biological function of SLAMF9 in glioma. Results: SLAMF9 expression was significantly higher in glioma tumor tissues than in normal tissues. High expression levels of SLAMF9 were correlated with shortened OS and DFS in glioma patients. Data from the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) glioma dataset revealed that the protein expression of CD68 and CD163 was positively related to SLAMF9 expression in the tissues of glioma patients. Conclusions: This study is the first to highlight the important clinical value of SLAMF9 in patients with glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.